Skip to main navigation Skip to search Skip to main content

Long-Term Remissions Observed in an Ongoing Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma.

  • Barbara Pro
  • , Ranjana H. Advani
  • , Pauline Brice
  • , Nancy L. Bartlett
  • , Joseph D. Rosenblatt
  • , Tim Illidge
  • , Jeffrey V. Matous
  • , Radhakrishnan Ramchandren
  • , Michelle A. Fanale
  • , Joseph M. Connors
  • , Yin Yang
  • , Dana A. Kennedy
  • , Andrei R. Shustov
  • Fox Chase Cancer Center
  • Stanford University
  • Hematology-Oncology, Hospital Saint Louis, Paris, France,
  • Washington University in St. Louis
  • University of Miami
  • Christie Hospital NHS, Manchester, United Kingdom,
  • Colorado Blood Cancer Institute, Denver, CO, USA,
  • Hematology-Oncology, Karmanos Cancer Institute, Detroit, MI, USA,
  • University of Texas MD Anderson Cancer Center
  • BC Cancer Agency
  • Seattle Genetics
  • University of Washington Medical Center

Research output: Contribution to journalArticlepeer-review

Original languageAmerican English
JournalBlood
Volume120
Issue number21
DOIs
StatePublished - Nov 16 2012
Externally publishedYes

Disciplines

  • Medicine and Health Sciences
  • Internal Medicine

Cite this